Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADCC and TACE in HBV-related HCC
NCT03086564Phase 2Completed
- Start
- May 2017
- Primary completion
- May 2020
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of HBV antigen/HepG2 lysate-pulsed dendritic cells in hepatocellular carcinoma (HCC) (2 arms). Primary endpoints: Imaging signs at 4 years, Alpha-fetoprotein (AFP) at 4 years and 1 more. Started May 2017; status: completed.
02
Drugs
HBV antigen/HepG2 lysate-pulsed dendritic cells
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03086564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03086564.